newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210